References
- Scottish Intercollegiate Guidelines Network, The British Thoracic Society. British guideline on the management of asthma. Thorax 2003;58(Suppl I):i1–i94
- British National Formulary [BNF]. London: British Medical Association; Royal Pharmaceutical Society of Great Britain; 2001
- Turner MO, Taylor DT, Bennett R, Fitzgerald JM. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. Am J Respir Crit Care Med 1998;157:540–6
- Gibson PG, Coughlan J, Wilson AJ, et al. Self-management education and regular practitioner review for adults with asthma (Cochrane Review). 2002 [Oxford, Update Software. The Cochrane Library, Issue 2]
- Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59(2):94–9
- Jones A, Pill R, Adams S. Qualitative study of views of health professionals and patients on guided self management plans for asthma. Br Med J 2000;321:1507–10
- Partridge MR, Barnes G, Price D, et al. Guided self management plans for asthma [letters]. Br Med J 2001;322:1121
- Price D, Wolfe S. Delivery of asthma care: patients’ use of and views on healthcare services, as determined from a nationwide interview survey. The Asthma Journal 2000;5:141–4
- National Asthma Campaign. Out in the open: a true picture of asthma today. http://www.asthma.org.uk/AsthmaAudit.pdf . 2001
- Jackson C, Lipworth B. Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract 1995;45(401):683–7
- Foresi A, Morelli MC, Catena E, on behalf of the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2001;119(1):309–10
- Ställberg B, Olsson P, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2004;57(8):656–61
- Ind PW, Haughney J, Price D, Rosen J-P, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 2004;98: 464–75
- Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20(2):225–40
- Campbell DA, Robinson DS. Cost advantages of combination asthma therapy. Treat Respir Med 2004;3(3):133–7
- Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997
- Levy MK. Primary care asthma management in the United Kingdom. Prim Care Respir J 2000;9(2):s15–s17
- Netten A, Dennett J, Knight J. Unit costs of health and social care 2000, 2000 ed. Canterbury: Personal Social Services Research Unit; 2000
- Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484–9
- Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32–8
- Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47(1):81–7
- Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. Br Med J 1998;316:690–3
- Price D, Haughney J, Duerden M, Nicholls C, Mosely C. The cost-effectiveness of CFC-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based upon a one year pragmatic, randomised clinical study. Pharmacoeconomics 2002;20(10):653–64
- Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of eformoterol Turbohaler® versus salmeterol Accuhaler® in children with symptomatic asthma. Respir Med 2002;96:250–8
- Sullivan S, Elixhauser A, Buist A, Luce B, Eisenberg J, Weiss K. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996;154(3):S84–S95
- NHS Executive. NHS reference costs. http://www.doh.gov.uk/ nhsexec/refcosts.htm, 2001
- Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6(4):327–40
- National Statistics website. Census 2001. http://www.statistics.gov.uk/census2001/demographic_uk.asp, 2003
- Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19–24
- Neville RG, Pearson MG, Richards N, et al. A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J 1999;14:605–9
- Mediplus IH. August 2002 MAT. 2002
- Lahdensuo A, Haahtela T, Herrala J, et al. Randomised comparison of guided self-management and traditional treatment of asthma over one year. Br Med J 1996;312:748–52
- Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmaco-economics 1999;15(3):241–56
- Thoonen B, van Weel C. Self management in asthma care [editorial]. Br Med J 2000;321:1482–3